Marshall Foundation Artificial Heart Laboratory, University of Arizona, Tucson, AZ, USA.
Artif Organs. 2010 Nov;34(11):885-90. doi: 10.1111/j.1525-1594.2010.01069.x.
Most infants and children implanted with ventricular assist devices (VADs) go on to cardiac transplantation. Recovery of dilated cardiomyopathies with the combination left ventricular decompression with a VAD and treatment with maximal medical therapy has been possible in some adults, and may be more feasible in infants and children. We used pulsatile and continuous flow VADs and the total artificial heart (TAH) as bridges to transplantation or to recovery. Candidates for native heart recovery were treated with maximal medical therapy for congestive heart failure and short-term dobutamine prior to weaning off device support. Since 1997, 28 infants and children, ages 1 month to 16 years, were implanted for durations of 3-107 days (mean 27). Eighteen received left VADs (LVAD), seven biventricular assist devices (BiVADs), and three TAHs. Device-related mortality was 7/28 (25%), leaving 21/28 (75%) surviving to transplantation or weaning from device support and 20/28 (71%) discharged from the hospital and currently surviving for 2 months to 9 years. Ten of 11 transplant recipients (90%) have survived 2 to 9 years. All 10 with recovered hearts are alive and well for 2 months to 5 years. Eight of 12 (67%) LVAD patients with dilated hearts recovered. None of the recovery patients were over 6 years old. Infants and children who have failed inotropic therapy may be treated with an LVAD and medical therapy for congestive heart failure anticipating native heart recovery. A variety of devices have been tried. All small LVADs yielded comparable results. Larger and older children also have a chance of recovery, but our experience with them is too small except to note that they do well with larger devices and transplantation.
大多数植入心室辅助装置(VAD)的婴儿和儿童最终会进行心脏移植。在一些成年人中,结合 VAD 进行左心室减压和最大药物治疗已经可以使扩张型心肌病得到恢复,而在婴儿和儿童中可能更为可行。我们使用搏动性和连续性血流 VAD 以及人工心脏(TAH)作为移植或恢复的桥梁。对于具有原生心脏恢复潜力的患者,在脱离设备支持之前,应使用最大药物治疗充血性心力衰竭,并短期给予多巴酚丁胺。自 1997 年以来,28 名年龄在 1 个月至 16 岁的婴儿和儿童接受了植入治疗,持续时间为 3-107 天(平均 27 天)。18 名患者接受了左心室辅助装置(LVAD),7 名患者接受了双心室辅助装置(BiVAD),3 名患者接受了 TAH。与设备相关的死亡率为 7/28(25%),21/28(75%)存活并进行了移植或脱离设备支持,20/28(71%)从医院出院并目前存活 2 个月至 9 年。11 名移植受者中有 10 名(90%)存活 2 至 9 年。所有 10 名恢复心脏功能的患者均存活 2 至 5 年。12 名 LVAD 扩张性心脏病患者中有 8 名(67%)恢复。没有恢复的患者年龄超过 6 岁。对正性肌力治疗无效的婴儿和儿童可使用 LVAD 和药物治疗充血性心力衰竭,预计会恢复原生心脏功能。已经尝试了多种设备。所有小型 LVAD 都取得了类似的结果。较大的和年龄较大的儿童也有恢复的机会,但我们的经验还太少,只能注意到他们在使用较大的设备和移植时表现良好。